1. A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain. (2nd November 2018) Authors: Gizzo, Salvatore; Ferrando, Marcos; Lispi, Monica; Ripellino, Claudio; Cataldo, Nazarena; Bühler, Klaus Journal: Journal of medical economics Issue: Volume 21:Number 11(2018) Page Start: 1096 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care. Issue 11 (November 2016) Authors: Colivicchi, Furio; Gulizia, Michele; Franzini, Laura; Imperoli, Giuseppe; Castello, Lorenzo; Aiello, Alessandro; Ripellino, Claudio; Cataldo, Nazarena Journal: Advances in therapy Issue: Volume 33:Issue 11(2016) Page Start: 2049 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Epidemiology of primary biliary cholangitis in Italy: Evidence from a real-world database. Issue 5 (May 2019) Authors: Marzioni, Marco; Bassanelli, Chiara; Ripellino, Claudio; Urbinati, Duccio; Alvaro, Domenico Journal: Digestive and liver disease Issue: Volume 51:Issue 5(2019) Page Start: 724 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. MO509: Reveal-CKD: Prevalence of Undiagnosed Stage 3 Chronic Kidney Disease Italy. (3rd May 2022) Authors: De Nicola, Luca; Peach, Emily; Barone, Salvatore; Ripellino, Claudio; Heiman, Franca; Tangri, Navdeep Journal: Nephrology dialysis transplantation Issue: Volume 37(2022)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Reply: RE: a cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy, and Spain. (3rd April 2019) Authors: Gizzo, Salvatore; Ferrando, Marcos; Lispi, Monica; Ripellino, Claudio; Cataldo, Nazarena; Bühler, Klaus Journal: Journal of medical economics Issue: Volume 22:Number 4(2019) Page Start: 381 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy. Issue 6 (19th February 2018) Authors: Malfertheiner, Peter; Ripellino, Claudio; Cataldo, Nazarena Journal: Pharmacoepidemiology and drug safety Issue: Volume 27:Issue 6(2018) Page Start: 581 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The risk of metabolic disorders in patients treated with asenapine or olanzapine: a study conducted on real-world data in Italy and Spain. (September 2014) Authors: Maina, Giuseppe; Ripellino, Claudio Journal: Expert opinion on drug safety Issue: Volume 13:Number 9(2014) Page Start: 1149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Unspecified intestinal malabsorption in patients treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: a retrospective analysis in primary care settings. Issue 11 (2nd November 2017) Authors: De Bortoli, Nicola; Ripellino, Claudio; Cataldo, Nazarena; Marchi, Santino Journal: Expert opinion on drug safety Issue: Volume 16:Issue 11(2017:Nov.) Page Start: 1221 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗